Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients

Open-label, non-randomized, multicentre phase 2 study with a safety run-in evaluating efficacy and safety of PQR309 in patients with relapsed or refractory lymphoma.

The maximum tolerated dose (MTD) of PQR309 in patients with advanced solid tumours was defined as 80 mg once daily given continuously (q.d. schedule) in a previous phase 1 study [8]. The safety run-in of this study will follow a modified 3 + 3 design to evaluate the safety of 60 and 80 mg PQR309 in patients with relapsed or refractory lymphoma administered p.o. once daily during a DLT (dose-limiting toxicity) period of 28 days.

In the safety run-in, three patients will be treated at 60 mg PQR309 for 28 days. Enrollment and treatment of all three patients may occur simultaneously as 80 mg PQR309 p.o. qd was established as the MTD maximum tolerated dose in solid tumours. Unless a DLT (dose-limiting toxicity) is observed in any of the three patients during the first 28 days of treatment, the investigators and the sponsor will decide to escalate the dose to 80 mg.Intermittent dosing schedules may be evaluated if, based on the overall evaluation of all the clinical and PK (pharmacokinetic) data from this and other studies with PQR309, data emerge during the step 1 of the phase 2 expansion in this PQR309 002A study, indicating that daily dosing of PQR309 is not adequately tolerated or inefficacious.

Intermittent dosing schedules may be evaluated if, based on the overall evaluation of all the clinical and PK (pharmacokinetic) data from this and other studies with PQR309, data emerge during the step 1 of the phase 2 expansion in this PQR309 002A study, indicating that daily dosing of PQR309 is not adequately tolerated or inefficacious.

Inclusion criteria

• Histologically confirmed diagnosis* of relapsed or refractory lymphoma, received at least two prior lines of therapy regardless of transformation status. Patients with relapsed chronic lymphoid leukemia (CLL) are eligible if they have received one or more prior lines of any approved standard therapy * archival biopsies may be used if obtained up to a year prior to enrollment; re-biopsy is strongly recommended if last biopsy was obtained more than a year ago.
• Only for patients in the Phase 2 part: At least one measurable nodal or extra-nodal lesion defined as follows: Clearly measurable (i.e. well-defined boundaries) in at least two perpendicular dimensions on imaging scan with > 1.5 cm in longest transverse diameter.
• Age ≥ 18 years
• Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-1 (See Appendix 2).
• Adequate organ system functions defined as:

• Absolute neutrophil count (ANC) ≥1.0x109/l
• Platelets ≥ 75x109/l
• Haemoglobin ≥ 85g/L
• Adequate hepatic function, defined as total bilirubin ≤ 1.5 times the upper limit of normal (ULN) and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN
• Adequate renal function, defined as serum creatinine ≤ 1.5 times ULN
• Fasting glucose < 7.0 mmol/L
• Ability and willingness to swallow and retain oral medication.
• Willingness and ability to comply with the trial procedures
• Female and male patients with reproductive potential must agree to use effective contraception from screening until 90 days after discontinuation of PQR309
• Signed informed consent1.5 cm in longest transverse diameter.

• Age >18 years 4. Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-1 5. Adequate organ system functions defined as:

• Absolute neutrophil count (ANC) >1.0x109/l
• Platelets > 75x109/l

Exclusion criteria

Any of the following conditions precludes enrollment of a patient:

• Immunosuppression due to:

• Allogeneic hematopoietic stem cell transplant (HSCT)
• Any immune-suppressive therapy within 4 weeks prior to trial treatment start
• Autologous stem cell transplant within 3 months prior to trial treatment start.
• Concomitant anticancer therapy (e.g. chemotherapy, radiotherapy, hormonal therapy, immunotherapy, biological response modifier, signal transduction inhibitors and steroids (steroids as maintenance for adrenal insufficiency are allowed)).
• Concomitant treatment with medicinal products that increase the pH (reduce acidity) of the upper gastrointestinal tract, including, but not limited to, proton-pump inhibitors (e.g. omeprazole), H2-antagonists (e.g. ranitidine) and antacids. Patients may be enrolled in the study after a wash-out period sufficient to terminate their effect (section 11.1.3.7).
• Use of any investigational drug within 21 days prior to trial treatment start.
• Patients who experienced National Cancer Institute (NCI) Common Terminology Criteria For Adverse Events (CTCAE) grade 4 on PI3K/mTOR inhibitors
• Any major surgery, chemotherapy or immunotherapy within 21 days prior to trial treatment start.
• Symptomatic or progressing central nervous system (CNS) involvement. Exception: Patients with meningeal involvement can be included upon discussion between the sponsor and the investigator.
• Persisting toxicities NCI CTCAE ≥2 related to prior anticancer therapy
• Presence of gastrointestinal disease or any other condition that could interfere significantly with the absorption of the study drug.
• Severe/unstable angina, myocardial infarction or coronary artery bypass within the last 3 years prior to trial treatment start, symptomatic congestive heart failure New York Heart Association (NYHA) Class 3 or 4, hypertension BP>150/100mmHg
• A serious active infection (e.g. chronic active hepatitis) at the time of treatment, or another serious underlying medical condition that could impair the ability of the patient to receive treatment.
• Lack of appropriate contraceptive measures (male and female)
• Pregnant or lactating women
• Known HIV infection
• Significant medical conditions which could jeopardize compliance with the protocol.
• Uncontrolled diabetes mellitus; patients with controlled diabetes may be enrolled (see fasting glucose levels in inclusion criteria).